Solventum Corp Files 8-K on Officer/Director Changes

Ticker: SOLV · Form: 8-K · Filed: 2025-10-21T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-appointment, director-election

Related Tickers: MMM

TL;DR

Solventum Corp (formerly 3M Health Care) filed an 8-K detailing changes in its leadership and compensation structure.

AI Summary

Solventum Corporation, formerly 3M Health Care Co, filed an 8-K on October 21, 2025, reporting events as of October 17, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Solventum Corporation is incorporated in Delaware and has its principal executive offices at 3M Center, Maplewood, Minnesota.

Why It Matters

This filing indicates significant corporate governance and executive changes within Solventum Corporation, which could impact its strategic direction and operational management.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding leadership and compensation, not indicating immediate financial distress or significant operational shifts.

Key Players & Entities

FAQ

What specific changes were made regarding directors or officers?

The filing indicates events related to the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as reported on October 17, 2025.

What is the former name of Solventum Corporation?

The former name of Solventum Corporation was 3M Health Care Co, with a date of name change noted as February 3, 2023.

When was the report filed with the SEC?

The 8-K report was filed with the SEC on October 21, 2025.

Where are Solventum Corporation's principal executive offices located?

Solventum Corporation's principal executive offices are located at 3M Center, Building 275-6W, 2510 Conway Avenue East, Maplewood, Minnesota 55144.

What is the SIC code for Solventum Corporation?

The Standard Industrial Classification (SIC) code for Solventum Corporation is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

From the Filing

0001628280-25-045731.txt : 20251021 0001628280-25-045731.hdr.sgml : 20251021 20251021170050 ACCESSION NUMBER: 0001628280-25-045731 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20251017 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20251021 DATE AS OF CHANGE: 20251021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solventum Corp CENTRAL INDEX KEY: 0001964738 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 922008841 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41968 FILM NUMBER: 251407786 BUSINESS ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 BUSINESS PHONE: 651-733-1110 MAIL ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 FORMER COMPANY: FORMER CONFORMED NAME: 3M Health Care Co DATE OF NAME CHANGE: 20230203 8-K 1 solv-20251017.htm 8-K solv-20251017 FALSE 0001964738 0001964738 2025-10-17 2025-10-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 17, 2025 SOLVENTUM CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware File No. 001-41968 92-2008841 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 3M Center, Building 275-6W 2510 Conway Avenue East , Maplewood , Minnesota 55144 (Address of Principal Executive Offices) (Zip Code) (Registrant’s Telephone Number, Including Area Code) ( 651 ) 733-1110 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $.01 Per Share SOLV New York Stock Exchange Securities registered pursuant to section 12(g) of the Act: None Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company      ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the exchange Act.     ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 21, 2025, Solventum Corporation (the “Company”) announced that Heather Knight has been appointed to serve in the newly created role of Chief Commercial Officer of the Company, effective as of November 10, 2025. Ms. Knight will oversee all global commercial and R&D operations across the Company’s MedSurg

View on Read The Filing